Antiresorptives and osteonecrosis of the jaw. (Q38049751)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Antiresorptives and osteonecrosis of the jaw (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Laurie K McCauley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

Journal of Evidence-Based Dental Practice

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

3 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

233-247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Recent advances in understanding the mechanism of action of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Clinical pharmacology of alendronate sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Biochemical and molecular mechanisms of action of bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonates: mechanism of action and role in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bone density and fracture risk in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Perspective. How many women have osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Alendronate-associated esophagitis: endoscopic and pathologic features

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Treatment of osteoporosis in chronic kidney disease and end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Safety of bisphosphonates in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

The acute-phase response after bisphosphonate administration

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

An In Vitro and In Vivo Study of Cytokines in the Acute-Phase Response Associated with Bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Activation of γδ T cells by bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Severely suppressed bone turnover and atypical skeletal fragility

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Periodontal assessment of postmenopausal women receiving risedronate

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Alendronate treatment of naturally-occurring periodontitis in beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Clinical Efficacy of 1% Alendronate Gel as a Local Drug Delivery System in the Treatment of Chronic Periodontitis: A Randomized, Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Clinical Efficacy of 1% Alendronate Gel in Adjunct to Mechanotherapy in the Treatment of Aggressive Periodontitis: A Randomized Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Postsurgical bone loss following root planing by ultrasonic and hard instruments

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Local Delivery of an Amino Bisphosphonate Prevents the Resorptive Phase of Alveolar Bone Following Mucoperiosteal Flap Surgery in Rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

A Histopathological Investigation on the Effect of Systemic Administration of the Bisphosphonate Alendronate on Resorptive Phase Following Mucoperiosteal Flap Surgery in the Rat Mandible

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Osteoporosis: a risk factor in periodontal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Mineral status of skeleton and advanced periodontal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Comparison of mandibular bone in normal and osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bone mineral content by photon absorptiometry of the mandible compared with that of the forearm and the lumbar spine

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Oral findings in osteoporosis. Part II: Relationship between residual ridge and alveolar bone resorption and generalized skeletal osteopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Alveolar bone response to submerged bisphosphonate-complexed hydroxyapatite implants

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Treatment of peri-implant defects with combination growth factor cement

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of 17beta-estradiol and alendronate on the removal torque of osseointegrated titanium implants in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of alendronate on endosseous implant integration: an in vivo study in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Association between oral bisphosphonate use and dental implant failure among middle-aged women

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Oral bisphosphonates and dental implants: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Updates on osteonecrosis of the jaw

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of zoledronate on oral wound healing in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effects of alendronate on bone healing after tooth extraction in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bone remodeling in maxilla, mandible, and femur of young dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Giant osteoclast formation and long-term oral bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Osteoradionecrosis of the mandible: pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bevacizumab-associated osteonecrosis of the jaw.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Osteonecrosis of the Jaw Related to Bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Medical contraindications to implant therapy: part I: absolute contraindications

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bone safety of long-term bisphosphonate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

More on the resolution of bisphosphonate-associated osteonecrosis of the jaw

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws.

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Teriparatide and osseous regeneration in the oral cavity

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

https://api.crossref.org/works/10.1016%2FS1532-3382%2812%2970046-5

7 January 2021

10.1016/S1532-3382(12)70046-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23040351%20AND%20SRC:MED&resulttype=core&format=json